Leiden, The Netherlands, April 28, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) the Dutch biopharmaceuticalcompany focusing on rare diseases with a high unmet medical need,today announced that it will present at the following USconferences: ▪ 66th American Academy of Neurology (AAN)Annual Meeting, Philadelphia, PA Poster presentation: Emerging ScienceSession: 6:15pm EDT on Wednesday, April 30, 2014 Drisapersen treatment for Duchenne muscular dystrophy:results of a 96-week follow-up of an open-label extension studyfollowing two placebo-controlled trials Presenter: Dr. Nathalie Goemans The poster includes results up to Week 48 from the secondopen-label extension study of drisapersen treatment in boys withDMD (DEMAND IV/DMD114349), who had previously completed a 48-week,double-blind, placebo-controlled treatment phase in one of twoPhase II feeder studies (DEMAND II/DMD114117 and DEMANDIII/DMD114044). Breakfast Briefing (by invitationonly) : 7:30 -9:00am EDT on Thursday, May 1, 2014 Corporate Update: Hans Schikan, CEO & GilesCampion, CMO Poster Presentation: Dr. Nathalie Goemans Q&A: Prosensa Management, Dr. NathalieGoemans (live) and Dr. Craig McDonald (by phone) Dr. Goemans is a pediatrician, child neurologist and Head of theNeuromuscular Reference Center for Children at the UniversityHospitals Leuven (UHL). She is actively involved in the developmentof protocols for international multicentre trials and is aninvestigator in clinical trials in Duchenne Muscular Dystrophy(DMD). Dr. McDonald is a Professor and Chair of Physical Medicine andRehabilitation and a Professor of Pediatrics at the University ofCalifornia Davis School of Medicine. He is an internationallyrecognized expert in the clinical management and rehabilitation ofneuromuscular diseases including muscular dystrophies and thedevelopment of novel outcome measures for clinicaltrials. ▪ 39th Annual Deutsche Bank Health CareConference, Boston, MA Fireside Chat: 2:10pm EDT on Wednesday, May 7,2014; Berndt Modig, CFO Live webcasts of Prosensa's presentations at the AAN BreakfastBriefing and the Deutsche Bank Health Care Conference will beaccessible through the Investors & Media section of thecorporate website at http://ir.prosensa.eu/events.cfmand will be archived for 90 days. Notes to editors About Prosensa Holding N.V. Prosensa (NASDAQ: RNA) is a Dutch biotechnology company engagedin the discovery and development of RNA-modulating therapeutics forthe treatment of genetic disorders. Its primary focus is on rareneuromuscular and neurodegenerative disorders with a large unmetmedical need, including Duchenne muscular dystrophy (DMD), myotonicdystrophy and Huntington's disease.
Prosensa's current portfolio includes six compounds for thetreatment of DMD, all of which have received orphan drug status inthe United States and the European Union. The compounds use aninnovative technique called exon-skipping to provide a personalizedmedicine approach to treat different populations of DMD patients. www.prosensa.com
CONTACT: Prosensa Holding N.V. Celia Economides, Senior Director IR & Corporate Communications Phone: +1 917 941 9059 Email: firstname.lastname@example.org